| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/07/2005 | WO2005030165A1 Dosage form for controlled release of an active agent formulation |
| 04/07/2005 | WO2005030159A1 Topical skin preparations for treatment of skin aging comprising a testosterone ester |
| 04/07/2005 | WO2005030158A1 Cosmetic composition comprising a tensioning agent and a particular block ethylenic polymer |
| 04/07/2005 | WO2005030157A1 Cosmetic or dermatological preparations having a content of isoflavones and licochalcone a |
| 04/07/2005 | WO2005030151A2 Compounds and compositions as protein kinase inhibitors |
| 04/07/2005 | WO2005030150A2 9,10-α,α-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THEREOF |
| 04/07/2005 | WO2005030149A2 Suppression of hiv replication for prevention and treatment of hiv |
| 04/07/2005 | WO2005030148A2 Tetrahydroindolone derivatives for treatment of neurological conditions |
| 04/07/2005 | WO2005030144A2 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| 04/07/2005 | WO2005030143A2 Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders |
| 04/07/2005 | WO2005030140A2 C-met modulators and methods of use |
| 04/07/2005 | WO2005030137A2 Improving biomechanical performance of irradiated biological material |
| 04/07/2005 | WO2005030134A2 Relationship of a specific metabolite to insulin resistance |
| 04/07/2005 | WO2005030132A2 Therapeutic regimens for administering drug combinations |
| 04/07/2005 | WO2005030131A2 Bis-quinazoline compounds for the treatment of bacterial infections |
| 04/07/2005 | WO2005030129A2 Quinoline potassium channel inhibitors |
| 04/07/2005 | WO2005030128A2 Pyrazole modulators of metabotropic glutamate receptors |
| 04/07/2005 | WO2005030127A2 Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 04/07/2005 | WO2005030125A2 Method of treating smallpox and monkeypox |
| 04/07/2005 | WO2005030121A2 Compounds, compositions and methods |
| 04/07/2005 | WO2005030120A2 Antiangiogenic agents |
| 04/07/2005 | WO2005030118A2 Targeted release of nitric oxide in the cns circulation for modulating the bbb and treating disorders |
| 04/07/2005 | WO2005030109A2 Regimen for the administration of rifamycin-class antibiotics |
| 04/07/2005 | WO2005030083A2 Methods and products which utilize n-acyl-l-aspartic acid |
| 04/07/2005 | WO2005029980A1 Composition with relieved unpleasant odor or taste of cysteines |
| 04/07/2005 | WO2005021559A3 Oxazaborolidines as bacteria effectors |
| 04/07/2005 | WO2005020973A3 Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine |
| 04/07/2005 | WO2005018528A3 Method for the treatment prophylaxis and differential diagnosis of prostatitis |
| 04/07/2005 | WO2005016960A3 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 04/07/2005 | WO2005016918A3 Heterocyclic n-aryl carboxamides as cytokine inhibitors |
| 04/07/2005 | WO2005016323A3 Use of c-kit inhibitors for treating type ii diabetes |
| 04/07/2005 | WO2005013947A3 Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer |
| 04/07/2005 | WO2005013946A3 Methods of treatment inflammatory bowel with lxr agonists |
| 04/07/2005 | WO2005012305A3 Tricyclic parp inhibitors |
| 04/07/2005 | WO2005012269A8 Novel azole compound |
| 04/07/2005 | WO2005009510A3 Penetration enhancer combinations for transdermal delivery |
| 04/07/2005 | WO2005009428A3 Orodispersible pharmaceutical composition of an antithrombotic compound |
| 04/07/2005 | WO2005009418A3 Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
| 04/07/2005 | WO2005009362A3 Muscarinic acetylcholine receptor antagonists |
| 04/07/2005 | WO2005009342A3 Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| 04/07/2005 | WO2005007647A9 Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 04/07/2005 | WO2005007094A3 Asthma and allergic inflammation modulators |
| 04/07/2005 | WO2005002591A8 Treatment psoriasis, impetigo, tinea by lipositol, cephalin and lecithin |
| 04/07/2005 | WO2005000845A3 Bicyclic derivatives as nk-1 and nk-2 antagonists |
| 04/07/2005 | WO2005000217A3 Combination therapy for the treatment of dyslipidemia |
| 04/07/2005 | WO2004113289A3 Glycosidase inhibitors and methods of synthesizing same |
| 04/07/2005 | WO2004113286A3 Mucin synthesis inhibitors |
| 04/07/2005 | WO2004112838A3 Codrugs of diclofenac |
| 04/07/2005 | WO2004112756A8 Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| 04/07/2005 | WO2004112719A3 Chemical compounds |
| 04/07/2005 | WO2004112715A3 Methods of making and using theaflavin,theaflavin-3-gallate, theaflavin-3’-gallate and theaflavin 3,3’ - digallate and mixtures thereof |
| 04/07/2005 | WO2004112714A3 Chemical compounds |
| 04/07/2005 | WO2004112709A3 Inhibitors of cathepsin s |
| 04/07/2005 | WO2004112695A3 Methods and compositions for delivery of catecholic butanes for treatment of obesity |
| 04/07/2005 | WO2004110383A3 Pharmaceutical composition and method for alleviating side effects of estrogen replacement therapy |
| 04/07/2005 | WO2004110357A3 Heterocyclic compounds and uses thereof |
| 04/07/2005 | WO2004110245A3 Combination therapy for cancer treatment |
| 04/07/2005 | WO2004108064A3 Diosgenin-based composition suitable for topical application |
| 04/07/2005 | WO2004098651A3 Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
| 04/07/2005 | WO2004096976A3 Spex compositions and methods of use |
| 04/07/2005 | WO2004096818A3 Method and compositions for identifying anti-hiv therapeutic compounds |
| 04/07/2005 | WO2004096206A3 Therapeutic combination of a cox-2 inhibitor and a tace inhibitor |
| 04/07/2005 | WO2004096158A3 Inhibiting viral infections |
| 04/07/2005 | WO2004096130A3 Inhibitors of akt activity |
| 04/07/2005 | WO2004093795A3 Compositions for delivery of drug combinations |
| 04/07/2005 | WO2004091596A3 Combination therapies for chronic obstructive pulmonary disease (copd) |
| 04/07/2005 | WO2004091538A3 Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| 04/07/2005 | WO2004091513A3 9-aminomethyl substituted minocycline compounds |
| 04/07/2005 | WO2004091488A3 Estrogen receptor modulators |
| 04/07/2005 | WO2004089369A3 Methods and means for treating protein conformational disorders |
| 04/07/2005 | WO2004089348A3 Use of a serotonin transporter inhibitor for the treatment of pulmonary hypertension |
| 04/07/2005 | WO2004087118A3 Synergistic combinations of macrolide t-cell modulator or inmunosuppressant and a retinoid |
| 04/07/2005 | WO2004075859A3 Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor |
| 04/07/2005 | WO2004062624A3 Method of treating nausea, vomiting, retching or any combination thereof |
| 04/07/2005 | WO2004062611A3 Anti-inflammatory cyclooxygenase-2 selective inhibitors |
| 04/07/2005 | WO2004062590A3 Bicyclic carbohydrates as antiprotozoal bioactive for the treatment of infections caused by parasites |
| 04/07/2005 | WO2004060322A3 Pharmaceutical preparations for treatments of diseases and disorders of the breast |
| 04/07/2005 | WO2004043228A3 Method of treating sepsis-induced ards |
| 04/07/2005 | WO2004041197A3 Methods of inhibiting glial scar formation |
| 04/07/2005 | WO2004037120A3 Implantable medical devices using zinc |
| 04/07/2005 | WO2004030618A3 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 04/07/2005 | WO2004020189A8 Embossable and writable multilaminate backing construction |
| 04/07/2005 | WO2004013309A3 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE |
| 04/07/2005 | WO2004002422A3 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 04/07/2005 | WO2004001072A3 Method for diagnosis of colorectal tumors |
| 04/07/2005 | WO2003082081A3 Use of rom production and release inhibitors to treat and prevent intraocular damage |
| 04/07/2005 | WO2003074101A8 Method of treating atherosclerosis and hypercholesterolemia |
| 04/07/2005 | WO2003074019A8 Whitening cosmetic composition |
| 04/07/2005 | WO2003072063A3 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| 04/07/2005 | WO2003030612A3 Methods for modulating activity of the fxr nuclear receptor |
| 04/07/2005 | WO2003028728A8 4-(4-substituted piperazinyl-1yl)-butylcarboxamides as d3 dopamine subtype selective ligands |
| 04/07/2005 | WO2003015783A8 Method of treating alcoholism or alcohol abuse |
| 04/07/2005 | US20050075619 Container for linezolid intravenous solution |
| 04/07/2005 | US20050075516 Anticarcinogenic agents formed by phosphorylation |
| 04/07/2005 | US20050075511 Prevention of human and/or animal viral, bacterial, fungal or parasitic infections; plant fungicides, bactericides and/or herbicides; reduced side effects; environmentally friendly; such as ((n-formyl-n-hydroxyamino)-methoxy)-methyl phosphonic acid disodium salt |
| 04/07/2005 | US20050075502 Cellulose tris (4-chlorophenyl carbamate) on stationary phase in liquid chhromatograhy column separates optical isomers |
| 04/07/2005 | US20050075499 For therapy of cancer |
| 04/07/2005 | US20050075493 Flea synaptic vesicle nucleic acid molecules, proteins and uses thereof |
| 04/07/2005 | US20050075407 Foam incorporating eutetic mixture |
| 04/07/2005 | US20050075404 Treating liver disease with menatetrerone for treating liver disorders and with descarboxy prothrombin |